Analyst Ratings For DURECT Corporation (NASDAQ:DRRX)
Today, HC Wainwright reiterated its Buy rating on DURECT Corporation (NASDAQ:DRRX) with a price target of $3.00.
There are 2 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on DURECT Corporation (NASDAQ:DRRX) is Buy with a consensus target price of $2.50 per share, a potential 72.41% upside.
Some recent analyst ratings include
- 7/31/2018-HC Wainwright Reiterated Rating of Buy.
- 10/20/2017-Stifel Nicolaus was Downgraded by analysts at Stifel Nicolaus from a “Buy ” rating to a ” Hold” rating. They now have a N/A price target on the stock.
- 9/27/2016-Rodman & Renshaw Reiterated Rating of Buy.
Recent Insider Trading Activity For DURECT Corporation (NASDAQ:DRRX)
DURECT Corporation (NASDAQ:DRRX) has insider ownership of 9.70% and institutional ownership of 44.81%.
- On 11/3/2016 April Fund L.P. 21, Major Shareholder, bought 95,000 with an average share price of $1.16 per share and the total transaction amounting to $110,200.00.
- On 9/26/2016 April Fund L.P. 21, Major Shareholder, bought 2,500,000 with an average share price of $1.15 per share and the total transaction amounting to $2,875,000.00.
- On 4/26/2016 April Fund L.P. 21, Major Shareholder, bought 5,500,000 with an average share price of $1.25 per share and the total transaction amounting to $6,875,000.00.
- On 4/26/2016 Dave Hoffmann, Director, bought 200,000 with an average share price of $1.25 per share and the total transaction amounting to $250,000.00.
- On 4/26/2016 Felix Theeuwes, Chairman, bought 160,000 with an average share price of $1.25 per share and the total transaction amounting to $200,000.00.
- On 3/14/2016 Armand Neukermans, Director, bought 18,000 with an average share price of $1.39 per share and the total transaction amounting to $25,020.00.
- On 3/14/2016 Felix Theeuwes, Chairman, bought 70,000 with an average share price of $1.41 per share and the total transaction amounting to $98,700.00.
About DURECT Corporation (NASDAQ:DRRX)
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Recent Trading Activity for DURECT Corporation (NASDAQ:DRRX)
Shares of DURECT Corporation closed the previous trading session at 1.49 −0.060 3.87% with 1.58 shares trading hands.